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Abstract
Background: The integrated Community Case Management (iCCM) of childhood illnesses strategy has been
adopted world over to reduce child related ill health and mortality. Community Health workers (CHWs) who
implement this strategy need a regular supply of drugs to effectively treat children under 5 years with malaria,
pneumonia and diarrhea. In this paper, we report the prevalence and factors influencing availability of medicines
for managing malaria, pneumonia and diarrhea in communities in central Uganda.
Methods: A cross sectional study was conducted among 303 CHWs in Wakiso district in central Uganda. Eligible
CHWs from two randomly selected Health Sub Districts (HSDs) were interviewed. Questionnaires, check lists, record
reviews were used to collect information on CHW background characteristics, CHW’s prescription behaviors, health
system support factors and availability of iCCM drugs. Multivariable logistic regression analysis was done to assess
factors associated with availability of iCCM drugs.
Results: Out of 300 CHWs, 239 (79.9 %) were females and mean age was 42.1 (standard deviation =11.1 years).
The prevalence of iCCM drug availability was 8.3 % and 33 respondents (11 %) had no drugs at all. Factors
associated with iCCM drug availability were; being supervised within the last month (adjusted OR = 3.70, 95 %
CI 1.22–11.24), appropriate drug prescriptions (adjusted OR = 3.71, 95 % CI 1.38–9.96), regular submission of
drug reports (adjusted OR = 4.02, 95 % CI 1.62–10.10) and having a respiratory timer as a diagnostic tool (adjusted
OR =3.11, 95 % CI 1.08–9.00).
Conclusions: The low medicine stocks for the community management of childhood illnesses calls for strengthening
of CHW supervision, medicine prescription and reporting, and increasing availability of functional diagnostic tools.
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Background
Although progress has been made in reducing under
five mortality in Sub Saharan Africa [1, 2], it is still a
huge challenge. The rate of decrease of under-five mor-
tality in Uganda from 1990 (160 per1000 live births) to
2006 (137 per 1000 live births) and now 90 per 1000
live births was good, but insufficient to achieve the Mil-
lennium Development Goal of 56 per 1000 live births
by 2015 [3, 4]. Three quarters of the under five deaths
are still due to a handful of causes such as malaria, pneu-
monia, diarrhea and newborn conditions [5, 6]. There-
fore, interventions that promote appropriate treatment
of childhood pneumonia, diarrhoea and malaria will
lead to major reductions in under five mortality. The
integrated Community Case Management (iCCM) of
common childhood illnesses (malaria, pneumonia and
diarrhea) has been widely adopted as a means to reduce
childhood morbidity and mortality by increasing access
to essential child health services [7, 8]. Under the iCCM
strategy, Community Health Workers (CHWs) are trained
to diagnose and treat sick children with malaria, pneu-
monia and diarrhea in communities. To this end, they
are provided with pre-packed medicines which include
amoxicillin for treating non severe pneumonia, Artemi-
sinin Combination Therapy (ACT) for uncomplicated
malaria, Oral Rehydration Salts (ORS) and zinc for
diarrhea. All patients are screened for the three diseases
and treatment is administered basing on the results of
the examination and diagnostic testing that includes:
malaria rapid diagnostic tests, disease history and re-
spiratory rates. This approach can result in a 70 % re-
duction in mortality from pneumonia in children under
age five, and reduce overall malaria mortality by 53 %
[9, 10]. Therefore, effective community case manage-
ment calls for an uninterrupted supply of medicines
and equipment necessary to promote early identifica-
tion and correct treatment of childhood diseases [11–13].
Child health programs often suffer shortages of key
products, which suggest that supply chain factors may
be adversely affecting outcomes of those programs
[14–17]. Poor supply chain management, including lim-
ited or none existent stock control and forecasting,
means that even though drugs may be available cen-
trally, there can be frequent stock-outs at community
level. Indeed supply chain management systems for na-
tional health systems coupled with prescriber’s training,
experience, use of guidelines and drug utilization rates,
often impact on the availability of medicines [18–20].
Since CHWs are the first level of contact between com-
munity and the health care system, stock-outs of essential
medicines for treating common childhood illnesses may
lead to delayed access to care thereby increasing child
mortality [21–23]. Although literature on the assessment
of drug availability in the formal health sector is widely
available [24–26], medicine availability for community
case management programmes for childhood malaria,
pneumonia and diarrhea has not been fully documented
in Uganda. Secondly, many studies addressing barriers
of access to essential drugs in developing countries
have mainly focused on the supply chain management
systems and not on the prescribers’ perspectives and
health system support factors such as training and
supervision [14, 16, 27]. Given the paucity of data on
the availability of drugs among CHWs, the objectives of
this study were to document the prevalence and factors
influencing availability of iCCM drugs in central Uganda.
Methods
Study setting
This study was conducted in Wakiso district. Wakiso lies
in the central region of Uganda about 12 km from
Kampala, the capital city of Uganda. Wakiso has a popu-
lation of 1,260,900 [4] and the top five major causes of
morbidity in the district are malaria, respiratory tract in-
fections, intestinal worms, skin diseases and diarrhea [4].
Malaria is endemic in the area and the under-five mor-
tality rate for the region is 128/1000 live births [4]. The
district is divided into seven Health Sub Districts
(HSDs). A HSD is the functional zone of the district
health system responsible for the delivery of maternal
and child health services, health promotion messages as
well as treatment of infectious diseases such as malaria.
Within the HSD are peripheral health facilities which
supervise CHW’s activities. Community Health workers
are provided with pre-packed medicines which include;
amoxicillin, Artemisinin-based Combination Therapy
(ACT), Oral Rehydration Salts (ORS) and zinc. Amoxi-
cillin is pre packed in two dose/strength formulations:
125 mg (red pack) for children aged 2 months to
12 months and 250 mg (green pack) for children from
12 months to 5 years. Likewise ACTs (Coartem*) is pre
packed in two dose formulations: 20/120 mg pack of 6
tablets (yellow pack) for children aged 2 months to
3 years and the 20/120 mg pack of 12 tablets for chil-
dren between 3 and 5 years. Each CHW takes care of
about 25 to 30 households.
Study design
This was a cross sectional study that employed quanti-
tative methods of data collection and the outcome of
interest was drug availability for the iCCM programme.
Eligible respondents were CHWs who had been re-
cruited on the iCCM programme for more than six
months by the time of the study in Wakiso district and
gave informed consent to participate in the study.
CHWs who were not available in the district during the
study period were excluded.
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Sample size calculation and sampling procedure
The sample size formula by Kish Leslie [28] was used
to calculate the required number of CHWs to partici-
pate in the study. A sample size of 305 CHWs was
calculated based on the following assumptions: a two
sided test with a precision of 5 %, and an estimated
prevalence of drug availability of 33 % [29]. The seven
HSDs in Wakiso were stratified into rural (4 HSDs)
and peri-urban (3 HSDs) and two were selected ran-
domly taking one from the rural HSDs and one from
the peri-urban HSDs. On average each HSD had about
180 CHWs managing sick children under the iCCM
programme. In each Sub County or town council
within the selected HSDs, we contacted the health facil-
ity managers or health workers responsible for CHWs
activities to obtain lists of CHWs responsible for iCCM
programme. We located the eligible CHWs in their
homes through their supervisors and local council/vil-
lage leaders.
Data collection and drug availability
A physical drug count of the four iCCM drugs (ACTs,
Amoxicillin, ORS and Zinc) was done on the day of the
interview using data extraction sheets and check lists.
Pretested semi structured questionnaires were adminis-
tered to collect information on factors affecting drug
availability. This tool captured socio-demographic in-
formation: individual, health system support factors
that may affect drug availability. A retrospective records
review of the iCCM patient registers for the previous
6 months was done to collect data on CHW’s drug pre-
scription behaviors. Specifically we looked at the diag-
noses and drugs prescribed by CHWs for each patient
seen in the last 6 months to determine whether the pre-
scriptions were appropriate basing on the iCCM treat-
ment guidelines.
A CHW was classified as having drugs when all the
four iCCM drugs were present on the day of the sur-
vey. Where a CHW only had some or none of the
four iCCM drugs, this was classified as no availability
of iCCM drugs. In addition, information on individual
drug availabilities and total stock-outs of all the four
drugs (absence of any drug) was captured.
Data collection tools were pretested and data was col-
lected by five trained research assistants who were su-
pervised by the principal investigator. Data collection
tools were translated into the local language (Luganda)
and back translated by other people without prior know-
ledge of the instrument.
Data analysis
Data were double entered in Epi-Info software version
3.3.2 of 2005 and analyzed using STATA 10 (STATA Corp,
College Station, TX, USA). Community health worker’s
background characteristics and drug availability were
summarized descriptively. Drug availability was dichot-
omized as “YES” if all the four iCCM drugs were avail-
able and “No” if only some or none of the drugs were
present. Relationships between CHWs background char-
acteristics, health system support factors and drug
availability were assessed using odds ratios. A p value
of less than 0.05 was taken to represent a statistically
significant association. All variables with a p-value of
less than 0.2 [30] at univariate analysis as well as vari-
ables known to predict medicine availability from litera-
ture such as prescriber’s education level, sex, occupation
and time since last training on dispensing drugs [31, 32]
were used in multivariable regression analysis. How-
ever, before conducting multivariable analysis, the ex-
istence of multicolinearlity was investigated using the
correlation coefficients between each pair of the inde-
pendent variables. Correlated variables (correlation co-
efficient value greater than 0.5 with a p-value less or
equal to 0.05) were excluded from the logistic regres-
sion analysis model. A binary logistic regression analysis
with a backward elimination method was done to deter-
mine independent factors associated with availability of
iCCM drugs. Conclusions were drawn based on the ad-
justed odds ratios with their corresponding 95 % confi-
dence intervals. Interactions among the independent
variables were not statistically significant. In order to
determine how well the model fit the data, Pearson chi-
squared test (p > 0.05) was used to determine the good-
ness of fit of the model.
Ethical considerations
Ethical approval to conduct this study was got from
Uganda National Council of Science and Technology,
Makerere University School of Public Health Higher
Degrees Research and Ethics Committee, and Wakiso
district health authorities. Written informed consent
was obtained from the study participants. Data accruing
from the study was kept securely locked at all times
and no personal identifiers were used or recorded on
any tools used for data collection.
Results
Of the 303 study participants, only 300 (99.0 %) were
included in our analysis. Data from three respondents
(1.0 %) were excluded from further analysis on account
of having incompletely filled data collection tools.
Table 1 shows background characteristics of respon-
dents. Majority 79.7 % of the respondents were females
and the mean age was 42.1 years (standard deviation
11.1 years). More than half, 65 % had secondary educa-
tion as the highest level of education attained while
only 14.3 % were in formal employment.
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Availability of iCCM drugs
Table 2 describes availability of iCCM drugs among
CHWs. Only 25 respondents (8.3 %) had all the four
iCCM medicines while 33 respondents (11 %) had no
drugs at all. ACTs/Coartem*-20/120 mg (6 tablet pack) a
drug used to treat malaria was the least available (at 3.3 %)
of all the iCCM medicines. Amoxicillin was the most
prevalent drug at 79 % for the 250 mg dose strength
(green pack) and 64.7 % for the 125 mg dose strength
(red pack).
Factors associated with availability of iCCM drugs among
CHWs
Table 3 describes associations between health system
factors and availability of iCCM drugs at unadjusted
analysis. Community health workers who were regularly
submitting monthly reports were more likely to have all
the four iCCM drugs (OR = 3.48 95 % CI 1.62–9.52)
compared to those who were not submitting reports.
Community Health workers who had more than 90 %
of their prescriptions done appropriately were more
likely to have all the iCCM drugs (OR = 3.32 95 % CI
1.33–8.32). Time since last training in dispensing iCCM
drugs, supervision from health workers and not having
diagnostic equipment (respiratory timer) were not associ-
ated with availability of iCCM medicines at crude analysis.
Table 4 shows results of the multivariable analysis of
independent factors associated with iCCM drug avail-
ability. When factors were fitted in a logistic regression
model for multivariable analysis, 99.5 % (n = 298) of re-
spondents were retained in the analysis. Factors that
were found to be independently associated with drug
availability were: being supervised within the last one
month (adjusted OR = 3.70,95 % CI (1.22–11.24), hav-
ing more than 90 % of prescriptions appropriately done
(adjusted OR = 3.71, 95 % CI 1.38–9.96), regular sub-
mission of monthly drug reports (adjusted OR = 4.02,
95 % CI, 1.62–10.10), Having a functional respiratory
timer as a diagnostic tool (adjusted OR =3.11,95 % CI,
1.08–9.00). In the multivariable model, we adjusted for
sex, prescriber’s education level, occupation and time
since the last training in dispensing drugs.
Discussion
Main findings
Overall, this survey showed low availability of drugs ne-
cessary to manage common childhood illnesses at com-
munity level in central Uganda. Less than 10 % of the
CHWs had all the four iCCM drugs for treating mal-
aria, pneumonia and diarrhea at the time of the survey.
Availability of iCCM drugs among CHWs was mainly
associated with timely submission of monthly drug re-
ports, supervision by health workers, and appropriate-
ness of prescriptions by CHWs, and having diagnostic
tools especially respiratory timers.
Implications for community care
Our results imply that over 90 % of the CHWs could
not effectively treat all the childhood conditions targeted
Table 1 Background characteristics of respondents
Variable Respondents (N = 300)
n (%)
Sex Male 61 (20.3)
Female 239 (79.7)
Age 20–29 years 28 (9.3)
30–39 years 85 (28.3)
40–49 years 100 (33.3)
50–50 years 77 (25.6)
>60 years 10 (3.3)
Education None/primary 68 (22.7)
Secondary 195 (65.0)
Tertiary 37 (12.3)








Occupation Unemployed 63 (21.0)
Formal employment 43 (14.3)
Self-employment 175 (58.3)
Others 19 (6.3)
Table 2 Availability of iCCM drugs among CHWs
Variable Availability of iCCM
drugs (N = 300, %)
Number of iCCMDrugs
All the four iCCM drugs 25 (8.3)
Only three of the iCCM drugs 69 (23.0)
Only two of the iCCM drugs 107 (35.7)
One of the iCCM drugs 66 (22.0)
No iCCM drug at all 33 (11.0)
Type of iCCM drugs
ACTs 20/120 mg 6 tablets pack (yellow) 10 (3.3)
ACTs 20/120 mg 12 tablets pack (blue) 106 (35.3)
Amoxicillin 125 mg pack (red) 194 (64.7)
Amoxicillin 250 mg pack (green) 237 (79.0)
Zinc 20 mg 79 (26.3)
Oral Rehydration Salts (ORS) 140 (46.7)
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under the iCCM policy on the day of the survey. This
could negatively impact on the strategy of using CHWs
to increase timely treatment of childhood conditions so
as to reduce childhood morbidity. In the management
of childhood illnesses, both dose strengths of ACTs
(Coartem*) are important because children require dif-
ferent dosages on the basis of age and weight, and sub-
stitution of doses may compromise the quality of care.
The low concurrent availability of the age specific packs
of ACTs (Coartem*) may lead to ineffective treatment
of malaria and this subsequently promotes irrational
drug use by CHWs. Irrational use of medicines can re-
sult in incomplete recovery, development of resistance
and adverse medicine reactions. For CHWs who pro-
vide curative treatment, the continuous supply of drugs
is an essential part of their effectiveness and thus re-
plenishment of drug supplies is necessary to maintain
the provision curative services in communities [33].
Intermittent drug supplies often lead to great declines
in care seeking for CHW services. When CHWs do not
have drugs, community members are often aware of the
stock-outs and seek care elsewhere [34, 35]. In addition,
drug availability is an important component of CHW
motivation [21] and indeed, lack of drugs has been
Table 3 Association between Health system factors and drug availability among CHWs
Variable Drug availability (N = 300) OR (95 % CI) P values
Yes (n, %) No (n, %)
Ever treating children above 5 years
Yes 2 (11.1) 16 (88.9) 1.00
No 23 (8.2) 259 (91.8) 0.71 (0.15–3.29) 0.660
Ever supplied drugs to care givers who have not brought sick children
Yes 1 (5.6) 18 (94.4) 1.00
No 24 (8.5) 257 (91.5) 1.68 (0.15–9.99) 0.829
Training on dispensing drugs
Within 6 months 1 (4.0) 24 96.0) 1.00
6 to 12 month 1 (4.4) 22 (95.6) 1.09 (0.06–19.07) 0.953
More 12 months 23 (9.1) 229 (90.9) 2.41 (0.31–18.77) 0.386
Having a respiratory timer
No 6 (4.7) 121 (95.3) 1.00
Yes 19 (9.9) 154 (90.1) 2.48 (0.93–7.69) 0.056
Supervision
No 19 (7.3) 240 (92.7) 1.00
Yes 6 (14.6) 35 (85.4) 2.16 (0.71–5.88) 0.179
Monthly reporting
No 9 (4.2) 182 (95.8) 1.00
Yes 16 (14.7) 93 (85.3) 3.48 (1.62–9.52) 0.011
Appropriateness of prescriptions
Less than 90 % 7 (4.3) 155 (95.7) 1.00
More than 90 % 18 (13.0) 120 (86.9) 3.32 (1.33–8.32) 0.006








Less than 90 % 1.00 1.00
More than 90 % 3.32 (1.33–8.32) 3.71 (1.38–9.96) 0.009
Having respiratory timers
No 1.00 1.00
Yes 2.48 (0.93–7.69) 3.11 (1.08–9.00) 0.036
Monthly reporting
No 1.00 1.00
Yes 3.48 (1.62–9.52) 4.02 (1.62–10.10) 0.003
Supervision by Health
workers in previous month
No 1.00 1.00
Yes 2.16 ( 0.71–5.88) 3.70 (1.22–11.24) 0.021
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shown to decrease their morale and the community’s
perception of their effectiveness [29].
Lack of diagnostic equipment may promote presump-
tive treatment of pneumonia leading to over prescrip-
tion of amoxicillin. Correct use of respiratory timers
not only improves diagnosis and treatment of pneumo-
nia but also leads to rational use of amoxicillin by
CHWs [36, 37]. A large number of the children who
die from pneumonia do so as a result of inappropriate
treatment due to misdiagnosis of symptoms. First level
health facility workers and CHWs diagnose pneumonia,
primarily through counting respiratory rates of children
with cough or difficulties in breathing. However, count-
ing respiratory rates is often challenging and even for
highly trained health workers, misclassifications are com-
mon. Pneumonia is often misdiagnosed as malaria by
CHWs and caregivers in resource poor settings until it
develops into a severe stage. Studies show that many
developing countries still face significant challenges in
the provision of effective health care, diagnosis and
treatment of pneumonia [38, 39]. Diagnostic support
aids for pneumonia are expected to contribute to im-
proved, more accurate diagnosis and classification of
pneumonia.
Community health workers are supposed to ensure
that the right information regarding drug consumption
and stock at hand is collected and made available to
right people who make informed decisions on the resup-
ply of drugs. Regular submission of drug reports enables
program coordinators to quantify drug needs based on
utilization. This may improve supply reliability and sup-
ply chain performance. In addition, it allows identifica-
tion of drug supply chain bottlenecks that may affect
programme implementation. When community level
drug needs are not carefully considered and estimated in
quantifications and procurements, CHWs are likely to
suffer the most from shortages and expiries since they
are at the end of the supply chain [17, 40].
Supervisors of CHWs are supposed to provide ongoing
support, identify best practices, challenges, provide feed-
back in a constructive way, in addition to suggesting
coping mechanisms. Additionally, they are supposed to
review CHW registers and cross check the drug inven-
tory to ensure that drugs are replenished regularly.
Through such interactions with CHWs, supervisors are
supposed to reinforce CHW’s competencies in case
management, drug use and record keeping.
Implications for research
Although low medicine stock-outs for treating childhood
conditions have been reported previously [16, 41],
concurrent stock-outs of the age specific packs for
ACTs and amoxicillin deserves serious attention as
this precludes any form of treatment for malaria and
pneumonia. When the age and weight specific drugs are
absent, CHWs tend to improvise treatments by dividing
larger pack sizes for lower age categories and combining
smaller packs for older children [42, 43]. Although this
still enables dispensing, it may compromise patient’s ad-
herence and treatment outcomes [44]. Indeed several
studies undertaken under the routine conditions of child
care have reported high levels of non-adherence [45, 46].
Nevertheless, the possible negative effects of the stock-
outs of the age-specific packs on patient’s adherence need
further investigation.
Whereas regular submission of drug reports may in-
crease drug availability as demonstrated in this study
and other studies in Malawi, Ethiopia and Rwanda [47],
the quality of such reports in terms of completeness,
accuracy and timeliness should be examined. These at-
tributes of data quality affect the usefulness of such re-
ports for decision making regarding the supply chain
for iCCM drugs. One of the challenges that may lead to
delays in reporting could be lack of transport to deliver
reports to health facilities and communication break-
downs between CHWs and their supervisors. As such, in-
novative ways to improve communication between CHWs
and the formal health system may enhance CHW’s per-
formance. Although supervision is key to CHW’s per-
formance [48], CHW supervision continues to be
reported as one of the weakest links in community
health programs [49, 50]. Thus it may be worthwhile to
investigate key bottlenecks in supervising CHWs so
that they are addressed.
Strengths and limitations
There are some limitations in the data that are worth
noting. In this study, drug availability was determined by
the presence of iCCM drugs with CHWs on the day of
the survey. Day of visit results do not show if iCCM
drugs have been in stock continuously, nor whether sup-
ply levels are too low or too high to avoid future stock-
outs. Missing data or incomplete filling of patient care
registers could have affected how the appropriateness of
drug prescriptions was assessed. Since this was a cross
sectional study, we cannot infer causality. We only we
report factors associated with drug availability other than
determinants of drug availability. However, this study
provides useful information on the availability of iCCM
drugs and the associated factors. Understanding and
identifying solutions to address drug constraints for the
community case management of childhood diseases may
yield substantial improvements in programme’s effective-
ness, scale up, and impact in reducing child mortality.
Conclusion
Medicine availability is a challenge for the iCCM program
in central Uganda. Under the iCCM program, CHWs are
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required to submit monthly drugs reports indicating
stock levels before receiving new drug stocks. Innovative
ways of improving supervision, reporting, prescribing
and availability of diagnostic tools may increase availabil-
ity of iCCM medicines. Improving availability of iCCM
drugs among CHWs is vital if iCCM is going to be suc-
cessful at treating childhood illness, and ultimately, redu-
cing child mortality.
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